Artal Group S.A. is Director & 10% Owner at LEXICON PHARMACEUTICALS, INC./DE (LXRX). They have made 11 open-market trades across 5 companies since 2012, most recently 2026-02-02.
8 open-market purchases totalling $114.1M since 2012, against 3 sales. Across 8 scored buys the stock is up 1.5% at ninety days, and 3.8 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 25% | 63% | 63% |
| Avg Move | -2.1% | +2.0% | +1.5% |
| Alpha | -2.5% | +0.6% | -3.8% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LXRX | BUY | 2026-02-02 | 2026-02-04 | $1.30 | $2.0M | -0.8% | +28.6% | +23.7% |
| CAVA | SELL | 2024-08-26 | 2024-08-28 | $116.36 | $698.2M | +3.3% | +6.8% | +23.8% |
| CAVA | SELL | 2024-06-05 | 2024-06-07 | $87.25 | $261.8M | +9.0% | +12.0% | +37.9% |
| LXRX | BUY | 2023-06-05 | 2023-06-05 | $2.60 | $72.2M | -1.2% | -13.1% | -36.9% |
| GLYC | BUY | 2023-02-21 | 2023-02-23 | $1.78 | $711K | -14.6% | -17.5% | +5.3% |
| SRRK | SELL | 2023-01-09 | 2023-01-11 | $9.48 | $10K | +24.8% | +6.7% | -21.2% |
| SRRK | BUY | 2023-01-05 | 2023-01-09 | $9.33 | $910K | +18.3% | +22.0% | -17.9% |
| GBIO | BUY | 2020-06-16 | 2020-06-18 | $19.00 | $15.2M | -2.0% | +6.8% | +39.4% |
| LXRX | BUY | 2018-05-31 | 2018-06-04 | $12.01 | $10.0M | +4.8% | +4.5% | -9.3% |
| SRRK | BUY | 2018-05-29 | 2018-05-31 | $14.00 | $6.3M | -0.1% | -15.9% | +6.9% |
| LXRX | BUY | 2012-10-23 | 2012-10-25 | $2.25 | $6.8M | -21.0% | +0.6% | +0.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.